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Bardet-Biedl syndrome (BBS) is an autosomal recessive, genetically heterogeneous, pleiotropic human disorder
characterized by obesity, retinopathy, polydactyly, renal and cardiac malformations, learning disabilities, and hy-
pogenitalism. Eight BBS genes representing all known mapped loci have been identiﬁed. Mutation analysis of the
known BBS genes in BBS patients indicate that additional BBS genes exist and/or that unidentiﬁed mutations exist
in the known genes. To identify new BBS genes, we performed homozygosity mapping of small, consanguineous
BBS pedigrees, using moderately dense SNP arrays. A bioinformatics approach combining comparative genomic
analysis and gene expression studies of a BBS-knockout mouse model was used to prioritize BBS candidate genes
within the newly identiﬁed loci for mutation screening. By use of this strategy, parathyroid hormone-responsive
gene B1 (B1) was found to be a novel BBS gene (BBS9), supported by the identiﬁcation of homozygous mutations
in BBS patients. The identiﬁcation of BBS9 illustrates the power of using a combination of comparative genomic
analysis, gene expression studies, and homozygosity mapping with SNP arrays in small, consanguineous families
for the identiﬁcation of rare autosomal recessive disorders. We also demonstrate that small, consanguineous families
are useful in identifying intragenic deletions. This type of mutation is likely to be underreported because of the
difﬁculty of deletion detection in the heterozygous state by the mutation screening methods that are used in many
studies.
Introduction
Bardet-Biedl syndrome (BBS [MIM 209900]) is a pleio-
tropic, autosomal recessive disorder characterized by
obesity, pigmentary retinopathy, polydactyly, renal ab-
normalities, learning disabilities, and hypogenitalism
(Bardet 1920; Biedl 1922; Green et al. 1989). The dis-
order is also associated with an increased susceptibility
to diabetes mellitus, hypertension, and congenital heart
disease (Harnett et al. 1988; Green et al. 1989; Elbedour
et al. 1994). BBS shows variable expressivity within and
between families, a ﬁnding that suggests genetic com-
plexity. The disorder also displays extensive genetic het-
erogeneity, and the involvement of two mutations at one
locus and a third mutation at a second locus has been
suggested (Katsanis et al. 2001). To date, eight BBS loci
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have been mapped, and the causative gene at each of
these loci has been identiﬁed (Kwitek-Black et al. 1993;
Shefﬁeld et al. 1994; Carmi et al. 1995; Young et al.
1999; Katsanis et al. 2000; Slavotinek et al. 2000; Nish-
imura et al. 2001; Mykytyn et al. 2001, 2002; Ansley
et al. 2003; Badano et al. 2003; Chiang et al. 2004; Fan
et al. 2004; Li et al. 2004). Mutation screening of the
eight known genes has resulted in the identiﬁcation of
approximately half of the causative mutations, indicat-
ing that additional BBS genes and mutations have yet
to be identiﬁed (Katsanis 2004; Hichri et al. 2005; V.C.S.
and E.M.S., unpublished data; L.G.B., unpublished
data).
The initial identiﬁcation of BBS genes relied heavily
on positional cloning, a process that begins with the
localization of genetic intervals, with the use of genetic
linkage studies of large multiplex families (Katsanis et
al. 2000; Slavotinek et al. 2000; Mykytyn et al. 2001;
Nishimura et al. 2001). Subsequently, bioinformatic
comparisons of protein sequences aided in the identi-
ﬁcation of additional BBS genes. For example, the po-
sitional cloning of the BBS1 gene was aided by the ﬁnd-
ing of limited sequence homology to BBS2 (Mykytyn
et al. 2002). BBS7 and BBS8 were identiﬁed by per-
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forming database searches for proteins with partial ho-
mology to BBS2 and BBS4, respectively (Ansley et al.
2003; Badano et al. 2003). The BBS3 and BBS5 genes
were recently identiﬁed using a combination of com-
parative genomics and positional cloning (Chiang et al.
2004; Fan et al. 2004; Li et al. 2004). The identiﬁcation
of additional BBS genes is hindered by the extensive
genetic heterogeneity and by the paucity of additional
large multiplex families for genetic mapping. To over-
come these obstacles in this study, we performed ho-
mozygosity mapping by the use of genomewide SNP
analysis of small (one or two affected individuals), con-
sanguineous BBS families, to identify potential new BBS
candidate regions, and we applied a bioinformatics ap-
proach that combines comparative genome analysis
with gene expression analysis of a Bbs4-null mouse
model to identify and prioritize BBS candidate genes.
The identiﬁcation of mutations in a gene found within
a candidate positional interval validates the use of small
families for the identiﬁcation of new BBS genes. Small,
consanguineous pedigrees also proved useful for the
identiﬁcation of patients with intragenic gene deletions
in three previously known BBS genes.
Material and Methods
Human Subjects
Signed informed consents approved by the institu-
tional review boards at the University of Iowa and col-
laborating institutions were obtained from all study par-
ticipants at the time of their entry into the study. The
diagnosis of BBS in individuals was based on the pres-
ence of at least three of the cardinal features of BBS
(obesity, polydactyly, renal anomalies, retinopathy,
hypogonadism, and learning disabilities). The features
most consistently observed in the patients recruited for
the study were obesity, polydactyly, and retinal degen-
eration. The 110 control samples (220 chromosomes)
used for allele frequency estimation in the general pop-
ulation included a subset of the DNA Polymorphism
Discovery Resource (Coriell Cell Repositories) and ad-
ditional samples matched to the BBS patient population.
The panel was designed to reﬂect the diversity present
in the human population (Collins et al. 1998).
SNP Homozygosity Mapping
Genomic DNA from affected individuals of consan-
guineous BBS families was used as the template to gen-
erate probes for use on Affymetrix 10K 2.0 SNP mi-
croarrays (Affymetrix). Sample processing and labeling
were performed in accordance with the manufacturer’s
speciﬁcations (Affymetrix). The arrays were hybridized,
washed, and scanned at the University of Iowa DNA
Facility. Chip images were processed by the GeneChip
DNA Analysis Software (GDAS) to generate SNP allele
calls. For the homozygosity analysis, a sliding window
of 30 SNPs was used to identify regions of homozygosity.
To allow for potential SNP miscalls, we incorporated
the use of quality control data to identify potential mis-
calls. To be conservative, we ignored SNPs that could
not be scored by GDAS for this analysis. For the samples
examined, an average call rate of 195% was obtained.
When more than one sample was available from a fam-
ily, a further constraint was placed on the analysis, in
that all the samples from a family were required to be
homozygous for the same allele at each SNP, consistent
with identity by descent.
STRP Genotyping
PCR ampliﬁcation for the analysis of STRPs was per-
formed using 40 ng genomic DNA in 8.4 ml reactions
containing 1.25 ml 10# PCR buffer (100 mM Tris-HCl
[pH 8.8], 500 mM KCl, 15 mM MgCl2, 0.01% gelatin
[w/v]); 200 mM each of dATP, dCTP, dGTP, and dTTP;
2.5 pmol of each primer; and 0.2 units of Taq poly-
merase. Samples were subjected to 35 cycles of 94C for
30 s (50C, 52C, 55C, or 57C, as required, for 30 s)
and 72C for 30 s. Ampliﬁcation products were sepa-
rated on 6% polyacrylamide gels containing 7.7 M urea
at 60 W, for ∼2 h. The bands were visualized by silver
staining. Oligonucleotide primers for the STRPs were
custom designed and synthesized commercially (IDT).
Comparative Genomic Analysis
Identiﬁcation and prioritization of BBS candidate
genes in this study used a computational comparative
genomics technique that is similar to previous methods
(Avidor-Reiss et al. 2004; Chiang et al. 2004; Fan et al.
2004; Li et al. 2004). A basic principle of the compar-
ative genomics approach is that a speciﬁc biological fea-
ture is evolutionarily conserved among a group of or-
ganisms. A second group of organisms that explicitly
lack this same characteristic is then identiﬁed. These two
groups of organisms serve as “positive” and “negative”
reference sets, respectively, for compiling a list of can-
didate genes. The organisms for our analysis were se-
lected with the goal of minimizing genome complexity.
In addition, ciliated organisms were included, since evi-
dence indicates that BBS genes are involved in cilia func-
tion and/or maintenance (Avidor-Reiss et al. 2004; Bl-
acque et al. 2004; Li et al. 2004; Mykytyn et al. 2004).
In a modiﬁcation of the comparative genomics approach
used to identify genes involved in cilia function (Chiang
et al. 2004; Fan et al. 2004; Li et al. 2004), Giardia
lamblia was included in the negative set despite the pres-
ence of ﬂagella, since no apparent BBS orthologues are
found in the Giardia genome. The inclusion of Giardia
allows for a more speciﬁc screen for BBS genes because
other cilia-related genes in the Giardia genome are re-
moved from the BBS candidate gene set. The compu-
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tational sequence similarity tool BLAST (Altschul et al.
1990) was used to determine the orthologs of human
proteins from Ensembl release 28.35a.1 to those of the
model organismsTrypanasoma cruzi, Leishmaniamajor,
G. lamblia, and Saccharomyces cerevisiae. The positive
and negative reference sets were compared using a
threshold of e-37 to identify BBS gene candidates. This
value was selected empirically on the basis of observed
levels of similarity among the known BBS proteins in
this group of organisms. Protein sequences for the model
organisms were obtained from The Institute for Ge-
nomic Research (T. cruzi), the Sanger Institute (L. ma-
jor), GiardiaDB (G. lamblia), and the Saccharomyces
Genome Database (SGD) (S. cerevisiae).
Bbs4 Microarray Analysis
The Bbs4/ mouse model has been described else-
where (Mykytyn et al. 2004). Whole eyes were dissected
from euthanized Bbs4/ and wild-type mice at 8 mo of
age. One eye from each animal was processed for his-
tological analysis to verify retinal degeneration, while
the second eye was used for the isolation of total RNA.
Total RNA from pooled Bbs4/ and wild-type eyes
(three in each group) was extracted using TRIzol reagent
(Invitrogen) and was puriﬁed through RNeasy columns
(Qiagen). Integrity of the RNA was assessed on an Agi-
lent 2100 bioanalyzer (Agilent Technologies). Pooling of
eyes was necessary because of the low RNA yield from
individual eyes and also to minimize the effects of bio-
logical variability among samples.
The two RNA pools were hybridized to Affymetrix
mouse 430 2.0 arrays. Five micrograms of total RNA
was used for the synthesis of double-stranded cDNA
by the Superscript Choice system (Invitrogen) and T7-
(dT)24 primer (Sigma-Genosys). In vitro transcription
was performed in the presence of biotinylated UTP, and
the cRNA was fragmented and hybridized for 16 h to
the arrays by use of the Affymetrix GeneChip Instru-
mention System at the DNA Core Facility of the Uni-
versity of Iowa. After stringent washes, the arrays were
stained with streptavidin-phycoerythrin (Molecular
Probes) and then scanned. Data were acquired using the
Affymetrix data collection and analysis programs
GeneChip Operating Software (GCOS) and GDAS.
Probe sets that demonstrated a greater than twofold de-
crease in expression in the knockout pool, as compared
with the wild-type pool, were identiﬁed. Such probe sets
were further constrained, in that the signal for at least
one of the pools was required to be scored as present
by GDAS.
DNA Sequencing and Mutation Screening
PCR products for sequencing were ampliﬁed in a 20-
ml reaction volume and were separated on a 2.0% aga-
rose gel, as described elsewhere (Nishimura et al. 1998).
The corresponding bands were excised and puriﬁed us-
ing the QIAquick gel extraction kit (Qiagen). As the
template for sequencing reactions using dye-terminator
chemistry (Applied Biosystems), 4.5 ml of puriﬁed PCR
product was used. PCR product sequencing reactions
were precipitated in the presence of glycogen and iso-
propanol. The reactions were analyzed on an ABI
3730XL DNA Sequencer. All sequence variants were
veriﬁed by direct DNA sequencing and/or by restriction
enzyme digestion. Primer sequences used to screen the
entire B1 gene are available upon request.
In some cases, the coding sequence of candidate genes
was also screened by SSCP analysis. Amplicons for SSCP
analysis were designed to be ∼200 bp in size. For SSCP,
PCR products were separated on SSCP gels (7 ml 50%
glycerol, 3.5 ml 5# TBE, 8.8 ml 37.5:1 acrylamide/bis,
and 50.7 ml ddH20) for 3–4 h in 0.5# TBE at room
temperature, with the temperature controlled by a cool-
ing fan. The gels were silver stained to visualize DNA
bands. Abnormal variants were sequenced and com-
pared with a control sample (CEPH sample 1331–01)
for the detection of any changes from that of the normal
sequence.
B1 Gene Expression Studies
Northern blots containing 2 mg of poly (A) RNA iso-
lated from a broad array of human and mouse tissues
were purchased from Clontech. Following hybridiza-
tion, the blots were stripped of radioactivity and rehy-
bridized with a cDNA probe for b-actin for the veriﬁ-
cation of equal loading of RNA (Swiderski et al. 1999).
RT-PCR was performed with the SuperScript II Reverse
Transcriptase kit (Invitrogen) in accordance with the
manufacturer’s instructions. Products were separated on
2.0% agarose gels. Bands were excised from the agarose
gels and sequenced, to conﬁrm their identities or to dis-




The existence of eight known BBS genes provided an
opportunity to use bioinformatic methods to identify
additional BBS genes. We hypothesized that the genomes
of model organisms that retained orthologues of the
known BBS genes were likely to contain yet-to-be-iden-
tiﬁed BBS genes, and the genomes of organisms that did
not contain orthologues of known BBS genes were un-
likely to contain orthologues of additional BBS genes.
We examined a number of model organisms for potential
inclusion in our comparative genomics analysis. Model
organisms such as T. cruzi, L. major, G. lamblia, and S.
cerevisiae were attractive for two reasons: These organ-
isms have relatively small genome sizes, and the paucity
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Table 1
Characteristics of BBS Proteins
Protein
Symbol Locus UniGene Location T. cruzia L. majora G. lambliaa Yeasta FCb Changec
BBS1 BBS1 Hs.502915 11q13.2 1e-62 2e-72 1.9 9.4 3.0 D
BBS2 BBS2 Hs.333738 16q12.2 3e-87 1e-76 0.2 0.068 2.6 D
ARL6 BBS3 Hs.373801 3q11.2 3e-41 9e-45 5e-32 3e-36 4.9 D
BBS4 BBS4 Hs.208681 15q24.1 3e-72 6e-80 5e-07 1e-08 9.9 D
BBS5 BBS5 Hs.233398 2q31.1 6e-69 2e-66 3e-17 1.5 5.3 D
MKKS BBS6 Hs.472119 20p12.2 2e-11 5e-07 1e-11 5e-13 1.2 NC
BBS7 BBS7 Hs.58974 4q27 8e-41 1e-39 1.7 0.44 2.3 D
TTC8 BBS8 Hs.303055 14q32.11 1e-79 3e-64 7e-20 5e-04 2.3 D
a Expected value of best match.
b Fold change in Bbs4/ eyes versus wild-type control eyes.
c Change in expression in Bbs4/ eyes versus wild-type control eyes. D p decrease and NC p no change.
of intervening intronic sequence facilitates the de novo
identiﬁcation of novel protein coding sequences. Table
1 illustrates the similarity of human BBS proteins to their
putative orthologues in these four organisms. With the
exception of the MKKS protein sequence, the known
BBS protein sequences have high levels of similarity to
sequences in T. cruzi and L. major. From these obser-
vations, a threshold of e-37 was used for considering
a gene found in a model organism to be an orthologue
of the human BBS gene. Based on this cutoff, BBS or-
thologues were not found in the genomes of G. lamblia
and S. cerevisiae.
We next performed BLAST analysis of the set of
35,838 human proteins from Ensembl release 28.35a.1
against the proteomes of T. cruzi, L. major, G. lamblia,
and S. cerevisiae. For the positive BBS candidate set, we
included all human proteins that exceeded the threshold
of e-37 to orthologues in T. cruzi and L. major. We then
removed from the BBS candidate set those human pro-
teins that did not meet the e-37 threshold in either G.
lamblia or S. cerevisiae, two organisms that do not con-
tain orthologues to the known BBS genes. The analysis
of G. lamblia orthologous proteins was especially help-
ful for the comparative genomic analysis, in that this
organism has four pairs of ﬂagella yet lacks identiﬁable
BBS orthologues. Several lines of evidence, including
evaluation of BBS mouse models and protein localiza-
tion, indicate that BBS genes are involved in cilia syn-
thesis, function, and/or maintenance (Avidor-Reiss et al.
2004; Blacque et al. 2004; Li et al. 2004; Mykytyn et
al. 2004). The use of the Giardia sequence allows re-
moval of cilia-related genes that may not be involved in
BBS. The removal of G. lamblia and S. cerevisiae pro-
teins resulted in a set of 366 human proteins, 239 of
which are unique. The genes corresponding to these pro-
tein sequences will be referred to as the “comparative
genomics” set of BBS gene candidates.
Reﬁnement of the BBS Candidate Gene Set with Gene
Expression Data
We have previously described elsewhere a knockout
mouse model for BBS4 (Mykytyn et al. 2004). Homo-
zygous knockout animals exhibit an early onset form of
retinal degeneration, with loss of the photoreceptor layer
by 8 mo of age. Gene expression studies were performed
by microarray analysis of whole eye RNA between
Bbs4/ versus age- and sex-matched controls. Photo-
receptor loss in the Bbs4/ animals was conﬁrmed by
histology. As shown in table 1, seven of the eight known
BBS genes demonstrate a twofold or greater decrease in
expression in eyes from Bbs4 knockout mice aged 8 mo,
as compared with control eyes. Only the Bbs6 gene,
Mkks, failed to show a signiﬁcant decrease in gene ex-
pression in this model system. Of the 45,000 probe
sets represented on the Mouse Genome 430 2.0 Array,
667 unique probe sets demonstrated a twofold or greater
decrease in gene expression in the knockout eyes, as
compared with the controls. This group of genes is re-
ferred to as the “retinal expression candidate gene set.”
We next hypothesized that, by considering the inter-
section of genes between the comparative genomics BBS
candidate gene set and the retinal expression candidate
gene set, we would be able to identify a reﬁned set of
genes that was highly enriched for potential new BBS
genes. There are a total of 19 genes that are found in
common in the bioinformatics and expression candidate
gene sets, including seven of the eight known BBS genes.
Because this set of 19 genes (table 2) contains known
BBS genes, it was hypothesized that this reﬁned set of
genes also included undiscovered BBS genes.
Homozygosity Mapping with Small, Consanguineous
BBS Pedigrees
Most of the previously identiﬁed BBS genes were iden-
tiﬁed using positional information obtained from genetic
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Table 2
BBS Gene Candidates Identiﬁed by Bioinformatics Analysis
Gene
Symbol UniGene BBS Location T. cruzia L. majora G. lambliaa Yeasta FDb
PLCL4 Hs.170156 … 1p36.32 2e-40 8e-43 0.033 2e-35 1.9
BBS5 Hs.233398 BBS5 2q31.1 6e-69 2e-66 3e-17 1.5 5.3
ARL6 Hs.373801 BBS3 3q11.2 3e-41 9e-45 5e-32 3e-36 4.9
PDE6B Hs.59872 … 4p16.3 6e-54 3e-54 2e-10 1e-13 84.5
BBS7 Hs.58974 BBS7 4q27 8e-41 1e-39 1.7 0.44 2.3
WDR17 Hs.532056 … 4q34.2 2e-58 3e-69 5e-19 3e-18 34.3
PDE8B Hs.78106 … 5q13.3 2e-42 1e-41 2e-21 4e-16 2.3
PDE6A Hs.151710 … 5q33.1 5e-48 1e-52 3e-07 3e-11 32.0
B1 Hs.372360 BBS9 7p14.3 3e-83 2e-67 0.43 1.6 2.6
CCDC2 Hs.145402 … 9p21.2 5e-56 7e-48 5e-21 2e-19 1.7
PDE6C Hs.93173 … 10q23.33 8e-53 1e-51 1e-11 9e-12 3.3
DPCD Hs.549129 … 10q24.32 4e-38 1e-40 6e-25 0.92 1.7
BBS1 Hs.502915 BBS1 11q13.2 1e-62 2e-72 1.9 9.4 3.0
TTC8 Hs.303055 BBS8 14q32.11 1e-79 3e-64 7e-20 5e-04 2.3
BBS4 Hs.208681 BBS4 15q24.1 3e-72 6e-80 5e-07 1e-08 9.9
PDE8A Hs.9333 … 15q25.3 3e-44 9e-43 2e-25 2e-17 2.3
BBS2 Hs.333738 BBS2 16q12.2 3e-87 1e-76 0.2 0.068 2.6
UNC119 Hs.410455 … 17q11.2 1e-38 1e-41 9e-07 0.91 6.5
MGC26694 Hs.303669 … 19p13.11 1e-49 5e-49 None 8e-33 2.0
a Expected value of best match.
b Fold decrease in Bbs4/ eyes versus wild-type control eyes.
Table 3







2p25.3-p24.1 87 21.5 7 …
4q24-q32.2 203 57.9 5 5, 6, 7
5q14.3-q23.1 124 32.1 7 1, 7
5q31.3-q32 37 2.7 6 3
7p22.2-p14.3 130 30.8 4 3, 8
7q32.3-q34 37 8.6 7 …
8p21.3-p12 45 9.7 7 …
8p12-q11.23 41 18.5 3 …
9q21.2-q22.1 265 11.4 2 4, 7
9q21.32-q31.2 76 23.6 7 1
9q33.1 83 2.4 1 …
10q22.1-q22.2 33 6.9 6 7
11p15.5-p15.3 45 9.6 5 …
12q15-q22 99 26.2 4 2, 4
14q11.2-q12 35 7.3 4 …
14q23.1-q24.2 51 12.7 3 3, 7
15q21.3-q22.2 61 4.8 6 3, 4
15q26.1-q26.3 158 9.9 2 …
16q22.1-q23.1 36 12.7 5 …
18q21.33-q22.1 43 2.7 6 3
a No. of contiguous homozygous SNPs deﬁning the can-
didate region.
b CAPs with a region of homozygosity that overlaps the
CSP-deﬁned candidate region.
mapping studies using multiplex families. We do not
have access to additional large families suitable for po-
sitional cloning studies. However, small, consanguineous
BBS families with one or two affected individuals can
be used to identify loci that are homozygous in the af-
fected individual(s). Loci that are homozygous by de-
scent in affected individuals from small, consanguineous
families are candidates for disease loci. Mapping data
from a small family typically identiﬁes a number of large
candidate intervals, only one of which includes the gene
that is mutated in that family. The intersection of pu-
tative candidate intervals identiﬁed by homozygosity
mapping with BBS candidate gene sets can lead to the
identiﬁcation of the highest priority candidate genes for
mutation screening.
To identify putative BBS loci, we performed genome-
wide SNP genotyping at 10,000 SNP density in two
groups of consanguineous BBS families. The ﬁrst group
contained seven families with two affected individuals
(consanguineous, affected sibling pairs [CSP]), while the
second group contained families with only one affected
individual. Homozygosity mapping studies in the ﬁrst
group of seven families revealed 20 candidate regions
(table 3). Only a single candidate region at 9q22 was
identiﬁed in more than one CSP family; all other can-
didate regions were identiﬁed in only a single CSP family.
The second group consisted of nine consanguineous BBS
families, each with one affected individual (consanguin-
eous affected proband [CAP]). Genotyping of the nine
CAP samples revealed 79 regions of homozygosity, 19
of which overlapped (at least partially) with regions
identiﬁed in the CSP families (see table 3). The data from
the homozygosity mapping studies were then compared
with the candidate gene set and were used to prioritize
candidate genes for mutation screening in selected BBS
patients. Three genes were initially selected for candi-
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Figure 1 Pedigrees of BBS families with B1 mutations. Speciﬁc mutations detected in each family are indicated below the family identiﬁer.
All mutations were found in the homozygous state, with the exception of that in UAP-74. mt p Mutant allele corresponding to the mutation
in each family. wt p Wild-type (normal) allele. In UAP-74, mt1 represents the K626fsX647 and mt2 represents the IVS41GrC mutation.
date gene screening—DPCD (Hs.549129, 10q24.32),
UNC119 (Hs.410455, 17q11.2), and B1 (Hs.372360,
7p14.3)—on the basis that these genes were those most
strongly supported from the homozygosity mapping
data (each mapped to an overlapping region of homo-
zygosity in one CSP family and in one CAP family, or
in two CAP families).
Identiﬁcation of B1 as the BBS9 Gene
The coding sequences of three candidate genes were
determined in DNA samples from those affected BBS
individuals who had a region of homozygosity that over-
lapped with the speciﬁc candidate gene. The DPCD and
UNC119 genes were sequenced without the ﬁnding of
BBS sequence variants. When theB1 gene was sequenced
in a consanguineous Arab BBS family (CAP-9) display-
ing homozygosity within the region of chromosome 7
containing the B1 gene, we detected a homozygous GrA
transversion that affects the splice donor site of intron
17 (IVS171GrA). This change was not found in 110
control samples (220 control chromosomes). The splice
donor mutation is predicted to prevent splicing at the
donor site, thus leading to the incorporation of intron
17 into the mature mRNA and resulting in premature
termination within intron 17. It was not possible to ex-
perimentally conﬁrm the effects of this mutation, since
cells or tissue were not available from this patient or
family members.
We next used SSCP to screen the B1 gene in 95 un-
related BBS probands with no known consanguinity (un-
related affected probands [UAP]). We detected ﬁve pro-
bands, each with a different mutation in the homozygous
state (see ﬁg. 1). These mutations include a homozygous
GrA transversion in exon 4 (421GrA) predicting
G141R, a homozygous CrT transversion in exon 9
(1063CrT) predicting Q355X, a homozygous CrT
transversion predicting R598X, a homozygous 1-bp in-
sertion (2046insC) predicting K683fsX687, and a ho-
mozygous 4-bp deletion (1887_1880delAACA) predict-
ing K626fsX647. The 1877_1880delAACA mutation
was also found in an affected proband (UAP-74) in the
heterozygous state. The UAP-74 family was also found
to harbor a splice donor mutation (IVS41GrC) in in-
tron 4 in the heterozygous state. In total, 6 of the 95
probands (6.3%) had either homozygous (5) or com-
pound heterozygous (1) mutations. In each case, the mu-
tation segregated with the disease in the family (ﬁg. 1).
None of these variants was detected in 110 control DNA
samples (table 4). All mutations refer to GenBank ref-
erence sequence NM_198428.
B1 Gene Structure and Expression
Previous studies have shown that the B1 gene encodes
multiple splice isoforms (Adams et al. 1999). A 1.8-kb
isoform appears to be speciﬁc to bone or bone-derived
cells. Two different isoforms of the B1 gene are listed in
UniGene as RefSeq ID numbers NM_014451 and
NM_198428. These two isoforms differ, in that exons
15 and 16 are present in NM_198428 but are absent in
NM_014451. Furthermore, two additional downstream
exons that are not present in either of the UniGene se-
quences have also been observed (Vernon et al. 2003).
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Table 4
BBS Mutations Detected in the B1 Gene
Gene Mutation Location Protein BBSa Controlsb
421GrA Exon 5 G141R 2 0
IVS51GrC Intron 5 Splice site 1 0
1063CrT Exon 10 Q355X 2 0
IVS171GrA Intron 17 Splice site 2 0
1792CrT Exon 18 R598X 2 0
1877_1880delAACA Exon 18 K626fsX647 3 0
2046insC Exon 19 K683fsX687 2 0
a No. of mutant alleles detected in 95 BBS samples.
b No. of alleles containing each variant detected in 110 unrelated
controls.
In an attempt to clarify the gene structure and expression
pattern of the B1 gene, we performed bioinformatics
analysis of B1 EST sequences and performed both north-
ern blot and RT-PCR studies on human tissues. These
studies indicate that the B1 gene consists of 25 exons
that span 1700 kb of genomic DNA. With the exception
of the ﬁrst exon, the remaining 24 exons contribute to
the various B1 protein isoforms. The NM_198428 iso-
form (presence of exons 15 and 16) appeared to be the
major isoform in all tissues examined, with little to no
expression of the NM_014451 isoform. We found evi-
dence for three splice isoforms at the 3′ end of the B1
gene, as depicted in ﬁgure 2. These three isoforms in-
volve differential utilization of exons 22, 23, 24, and
25, along with the use of alternative 3′ UTR sequences.
Multiple B1 transcripts have been previously reported
elsewhere in a broad range of human tissues (Adams et
al. 1999). To study B1 gene expression patterns in tissues
related to the BBS phenotype in mouse and human, we
prepared northern blot hybridization probes directed at
exons 18–20, as depicted in ﬁgure 1. We observed ex-
pression of a 4.5-kb transcript in all tissues studied, as
well as several smaller transcripts ranging in size from
∼2 kb to 4 kb, as shown in ﬁgure 3A. Similarly, in mouse
tissues, expression of an ∼4.5-kb mRNA was noted (ﬁg.
3B). Two additional smaller transcripts were detected
solely in the testis. B1 gene expression was also noted
in the eye and in many regions of the mouse brain, in-
cluding the hypothalamus (data not shown).
Alu-Mediated Deletions as a BBS Mutation Mechanism
In addition to the identiﬁcation of a novel BBS gene,
homozygosity mapping of individual patients from con-
sanguineous matings was useful for facilitating the iden-
tiﬁcation of previously undetected mutations in known
BBS genes. Examination of the SNP data from nine un-
related BBS patients revealed that six were homozygous
for at least one locus containing known BBS genes (table
5). We sequenced the known BBS gene at the homozy-
gous locus in each of these individuals. No point mu-
tations were detected within the coding regions or the
ﬂanking intron regions of the BBS genes that were ex-
amined. However, it was noticed that some of the am-
plicons consistently failed to amplify from theDNA sam-
ples of three affected patients. Since the samples used
for this analysis were obtained from consanguineous
BBS families, the presence of deletions in the homozy-
gous state was considered as the cause of the failed am-
pliﬁcation. In each case, deletions were conﬁrmed and
characterized by the examination of regions that ﬂanked
the exons that failed to amplify in the BBS-affected in-
dividuals. The regions of the BBS genes containing these
deletions are shown in ﬁgure 4.
Exons 9, 10, 11, and 12 failed to amplify from a
proband (CAP-2) that demonstrated homozygosity for
a ∼68-Mb region on chromosome 2 that contains the
BBS5 gene. Characterization of the deletion conﬁrmed
that the breakpoints were located within intron 8 and
a region beyond the BBS5 3′ UTR. The breakpoint in
intron 8 was found to have occurred within an Alu
element, while the downstream breakpoint occurred
within an SVA repeat element. There was no apparent
sequence similarity at the site of the breakpoints other
than a short region that ﬂanked the breakpoints. No
other family members were available for study.
Exons 1, 2, 3, and 4 failed to amplify from a proband
(CAP-8) that demonstrated homozygosity for a 17-Mb
region on chromosome 4 that contained the BBS7 gene.
Characterization of this region of homozygosity con-
ﬁrmed a four-exon deletion with breakpoints that were
located upstream of exon 1 and within intron 4. The
breakpoint upstream of exon 1 was found to have oc-
curred immediately 3′ of an Alu element, whereas the
breakpoint within intron 4 appeared to occur within a
nonrepetitive sequence. There was no apparent sequence
similarity at the breakpoint regions. There were four
other family members available for study, none of which
had BBS. The BBS7 deletion was not found in the ho-
mozygous state in any of these family members.
Evaluation of the BBS4 gene in a proband (CAP-1)
with a 30-Mb region of homozygosity on chromosome
15 revealed the ampliﬁcation failure of exons 3 and 4.
Further analysis conﬁrmed a two-exon deletion with
breakpoints within introns 2 and 4. This mutation was
identical to that reported in two other families with a
deletion in BBS4 (Mykytyn et al. 2001). The small sizes
of these deletions (10 kb–20 kb), in comparison with
the average 300-kb spacing of SNPs on the array used
for this study, precluded their direct detection by SNP
genotyping.
We examined the regions containing the breakpoints
in each of the three deletion events. Three of the six
breakpoints occurred within Alu-repetitive elements,
whereas a fourth was found to occur just outside an Alu
element. The two breakpoints involved in the BBS4 de-
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Figure 2 Genomic structure of the B1 gene, with exons depicted as boxes. Filled boxes, Coding regions. Open boxes, UTRs. Exon sizes
are shown below the exons in the genomic structure. The three isoforms of B1 presented in this study are depicted below the genomic structure.
The location of the B1 northern blot probe (hatched box) is shown. Locations of the BBS mutations detected in this study are indicated at the
bottom of the ﬁgure.
letion appear to have occurred within the Alu element
in regions that share sequence similarity (ﬁg. 5). It has
been previously noted elsewhere that this sequence
shows a striking resemblance to the prokaryotic x-se-
quence, which is thought be involved in stimulating re-
combination in E. coli (Rudiger et al. 1995; Kolomietz
et al. 2002). The close proximity of Alu elements to at
least one of the regions involved in each of the deletion
events suggests that such elements play some role in their
occurrence.
Discussion
Although BBS is uncommon in the general population,
some clinical features of the disorder, such as hyperten-
sion, obesity, and diabetes, are prevalent. Several BBS
genes have been identiﬁed to date, yet our knowledge
of BBS gene function remains limited. The identiﬁcation
of additional BBS genes remains a worthy goal for a
number of reasons, including that (1) accuratemolecular
diagnosis of this disorder is not currently possible for
many patients, (2) additional clues to a common mo-
lecular mechanism involved in BBS pathogenesis may be
elucidated by the identiﬁcation of additional genes, (3)
a clearer understanding of the genetic complexity of BBS
will be aided by the identiﬁcation of additional genes,
and (4) identiﬁcation of additional BBS genes is likely
to give insights into the pathways involved in individual
components of the BBS phenotype.
Before the current study, eight BBS loci were known,
and the disease-causing gene at each of these loci was
identiﬁed using positional cloning and candidate gene
analysis. On the basis of mutation analysis of coding
sequence from the eight known genes, the disease-caus-
ing mutation has been identiﬁed in approximately half
of the patients. Possible explanations for such a result
include the existence of as-yet-unidentiﬁed BBS genes,
the existence of undetected mutations in one or more
of the known BBS genes, and/or misdiagnosis of BBS
patients. The current study was based on the hypothesis
that additional BBS genes are yet to be discovered.
The genetic attributes of BBS presents obstacles that
impede mapping efforts, including the genetic hetero-
geneity of the disorder, the relative rarity of the disorder,
and the paucity of multiplex families. To overcome these
obstacles, we generated and utilized three types of data.
First, we performed homozygosity mapping in small,
consanguineous BBS pedigrees with one or two affected
individuals. Second, we utilized comparative genomics
data to generate a set of BBS candidate genes that are
conserved in the genomes of model organisms in a pat-
tern similar to the currently known BBS genes. Finally,
we used comparative expression data generated by mi-
croarray analysis of Bbs4/ and control mouse eyes.
The combination of these three types of data allowed
us to select high-priority genes for mutation screening
in selected BBS patients.
To take maximum advantage of small pedigrees to
identify new genetic loci involved in BBS, we selected
pedigrees in which the parents of the patients were
known to be related. The use of consanguineous pedi-
grees allowed homozygosity mapping to be performed.
The size of the pedigrees did not provide enough power
to unambiguously map new loci. However, modest den-
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Table 5
Screening of Known BBS Genes in CAP Patients
Gene
CAP




BBS3 4 NC 3p13-q12.3 68 31.7
BBS4 1 DEL 15q22.31-q26.1 99 29.6
BBS4 4 NC 15q14-q26.1 197 54.5
BBS5 2 DEL 2q12.3-q31.1 226 67.8
BBS6 1 NC 20p13-q13.13 152 47.2
BBS6 7 NC 20p12.3-p12.1 187 6.9
BBS7 5 NC 4q25-q28.1 37 13.1
BBS7 7 NC 4q26-q31.1 567 26.1
BBS7 8 DEL 4q26-q26.3 372 16.6
a Results of screening the coding region of a known BBS gene. NC
p no change and DEL p large intragenic deletion.
b No. of contiguous homozygous SNPs deﬁning the candidate
region.
Figure 3 Northern blot analysis of B1 gene expression by northern blot analysis. A, Human B1 probe hybridized to human RNA. B,
Mouse B1 probe, corresponding to the same location as the human B1 probe, hybridized to mouse RNA samples.
sity SNP genotyping of the small, consanguineous ped-
igrees did identify candidate BBS loci on the basis of
the identiﬁcation of regions with apparent homozygos-
ity by descent. SNP genotyping of individual patients
revealed numerous homozygous SNPs. In most cases,
individual SNPs are homozygous by state. However,
large stretches of consecutive homozygous SNPs are
more likely to be homozygous by descent in the off-
spring of consanguineous matings than they are to be
homozygous by state. In this study, we used a sliding
window of 30 SNPs to stringently identify regions of
homozygosity, since even relatively uninformative SNP
markers are unlikely to be homozygous by state for 30
consecutive markers. The requirement of 30 consecutive
homozygous SNPs limited the number of false positive
regions yet allowed for the identiﬁcation of large regions
of homozygosity. Because any individual is likely to
have multiple homozygous intervals, genetic intervals
identiﬁed in this manner can be considered only as pu-
tative disease loci. However, such loci are useful for
prioritizing the selection of candidate genes for muta-
tion screening, and this application of homozygosity
data was used successfully in this study. In future stud-
ies, the use of higher-density SNP genotyping and the
use of genetic and physical map position of the SNPs
may allow for the detection of smaller disease candidate
regions that are homozygous by descent in other
families.
Comparative genomics has been utilized to facilitate
the identiﬁcation of the two most recently identiﬁed BBS
genes, BBS3 and BBS5 (Chiang et al. 2004; Fan et al.
2004; Li et al. 2004). In the current study, we have
reﬁned this approach by selecting two core sets of ge-
nomes of model organisms for comparative genomic
analysis. An important improvement was the use of the
genome of G. lamblia, a bi-nucleated organism, with
four pairs of ﬂagella, and one of the most primitive
known eukaryotic organisms. It contains no ortho-
logues of the known BBS genes, despite the presence of
ﬂagella. This observation suggests that BBS genes are
not required for biogenesis or maintenance of the ﬂa-
gella in Giardia. Because Giardia has ﬂagella, the Giar-
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Figure 4 Intragenic deletions found in BBS4, BBS5, and BBS7. The extent of each deletion is depicted within the partial genomic structure
for each gene. The locations of the exons are shown below the line representing the genomic sequence (AC016402, AC093899, andAC079341).
Within the genomic sequence, repetitive element family members are indicated as follows: blue, AluS; red, AluJ; green, AluY; yellow, FLAM;
and pink, SVA. Translation of the genomic region in the three forward reading frames are shown below each gene ﬁgure with start codons
(green) and stop codons (red).
dia genome should contain the genes that are required
for generating and maintaining ﬂagella. It is the sub-
traction of this particular set of genes during the com-
parative genomics analysis that made the genome se-
quence of Giardia a key resource in deﬁning BBS
candidate genes.
A third component to our approach to identifying
novel BBS genes was the use of gene expression analysis
of a BBS mouse knockout model. We have previously
characterized the Bbs4/ mouse model and found that
the homozygous mutant mice underwent an early onset
retinal degeneration, with loss of the photoreceptor
layer by 8 mo of age (Mykytyn et al. 2004). The loss
of the photoreceptor layer provided an opportunity to
use this animal model to identify genes that are ex-
pressed in the photoreceptor layer by using microarray
analysis to compare knockout and control animals. In
addition to theBbs4 gene, six of the seven knownmouse
BBS genes showed signiﬁcantly decreased expression in
the Bbs4-knockout eye. This suggests that the BBS genes
are expressed predominantly in the photoreceptor layer,
though they may also be expressed at lower levels in
other regions of the eye. Importantly, we would expect
that other, as-yet-unidentiﬁed BBS genes would dem-
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Figure 5 Sequence ﬂanking the breakpoints for the BBS4 deletion. The sequences of the 5′ and 3′ Alu elements are shown as well as the
sequence of the junction fragment of the BBS4 deletion event in family CAP-1. Box, The region in which the breakpoint has occurred within
each Alu element. The 26-bp core sequence within the Alu element identiﬁed by Rudiger et al. (1995) is shown at the bottom of the ﬁgure, as
well as a comparison to the prokaryotic x-sequence.
onstrate similar expression in the photoreceptor layer,
which would, in turn, make their identiﬁcation by mi-
croarray analysis possible.
Seven of the eight known BBS genes are found in both
the comparative genomics and gene expression candi-
date gene sets. Each set individually has hundreds of
potential candidate genes. By identifying genes that were
found in both candidate gene sets, it was possible to
deﬁne a set of 19 gene candidates that had a very high
probability of being mutated in patients with BBS. Only
the BBS6 gene, MKKS, is not contained in this list of
BBS gene candidates. In fact, the MKKS gene does not
satisfy criteria for inclusion into either the comparative
genomics or gene expression candidate gene sets.
We conducted homozygosity mapping studies in 16
consanguineous BBS families, each containing only one
or two affected individuals. The information gained
from the mapping studies was used to select those BBS
patients that were most likely to harbor mutations in
speciﬁc candidate genes. This strategy resulted in the
identiﬁcation of the B1 gene on chromosome 7p as a
novel BBS gene.
Multiple lines of evidence support the conclusion that
the B1 gene is BBS9. A total of seven mutations were
detected in the B1 gene in DNA samples from BBS pa-
tients. None of these mutations was detected in controls.
Of note, all but one of the seven probands in which
mutations were found were homozygous for their spe-
ciﬁc mutation (one patient was a compound heterozy-
gote), despite the fact that the majority of these families
were not known to be consanguineous. This ﬁnding was
predicted for disease-causing loci on the basis of the
observation of Sir Archibald Garrod (1902) that pa-
tients with rare autosomal recessive disorders weremore
likely than not to result from consanguineous unions.
Furthermore, the tissue expression pattern was similar
to that of other BBS genes. The B1 gene has also been
shown to be expressed in ciliated cells in C. elegans, a
ﬁnding that has been observed for other BBS genes (Bl-
acque et al. 2004). The B1 protein has no similarity to
the other known BBS proteins and the speciﬁc function
of the B1 gene is unknown.
In addition to identifying a novel BBS gene, we also
used homozygosity mapping to identify three families
with homozygous deletions in three different BBS genes
(BBS4, BBS5, and BBS7). These deletions are predicted
to result in null alleles. They were discovered fortui-
tously in the consganguineous samples, because of the
inability to amplify certain exons from samples with the
deletions. However, in the heterozygous state, such de-
letions would not be detected by current screeningmeth-
ods, since the remaining copy of the BBS gene would
provide an adequate template for PCR ampliﬁcation.
Thus, it is likely that some samples for which only a
single BBS mutation is detected may actually harbor an
undetected deletion or duplication. The existence of pa-
tients with BBS who are heterozygous for a single BBS
mutation has been used as an argument for the triallelic
hypothesis of BBS inheritance (Beales et al. 2003). Large
deletions (or duplications) may be the second mutation
in some samples for which only a single mutation has
been detected. Other types of mutations that are not
detected by standard mutation screens include promoter
and other regulatory mutations, some of which may be
located at a large distance from the ﬁrst exon of the
gene. Together, these classes of mutations might explain
cases in which only a single causative BBS mutation has
been identiﬁed.
In addition to the identiﬁcation of regions of ho-
mozygosity, it is possible to use SNP genotyping for the
identiﬁcation of deleted regions of the genome. In the
current study, we did not identify novel BBS candidate
regions on the basis of the identiﬁcation of microdele-
tions with the use of SNP genotyping. However, the use
of higher-density SNP arrays could facilitate the iden-
tiﬁcation of relatively small deletions, either by detecting
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regions of apparent homozygosity or, in the case of ho-
mozygous deletions, by the failure of contiguous SNPs
to give a detectable signal on the array.
In summary, we have used a multifaceted approach
that combines comparative genomics analysis with gene
expression information from a BBS-knockout model, to
identify a focused set of BBS candidate genes. Small,
consanguineous BBS families were used to identify can-
didate regions for new BBS loci. By use of this infor-
mation, the B1 gene was identiﬁed as a new BBS gene,
BBS9. The identiﬁcation of BBS9 demonstrates that
small, consanguineous BBS families can be used suc-
cessfully to identify new BBS genes. The mapping in-
formation was also used to identify three intragenic de-
letions within the BBS4, BBS5, and BBS7 genes. Since
this type of mutation is not detected by the commonly
used mutation detection strategies, the frequency of
such mutations in the BBS population is largely un-
known and may represent a class of mutation that is
underestimated. The approaches used in this study
would be applicable to numerous other autosomal re-
cessive disorders.
Acknowledgments
We are grateful to the patients and their families for partic-
ipating in this study.We thankM. Andrews, G. Beck, K. Bugge,
T. Kucaba, R. Mullins, A. Nalley, and M. Olvera, for technical
assistance, and D. Aguiar-Crouch, for administrative assis-
tance. This work was supported by the following grants and
organizations: National Institutes of Health grants P50-HL-
55006 (to V.C.S.) and R01-EY-11298 (to V.C.S. and E.M.S.);
Carver Endowment for Molecular Ophthalmology (to E.M.S.
and V.C.S.); Research to Prevent Blindness (to the Department
of Ophthalmology, University of Iowa); the University of Iowa
(to D.Y.N.); and the intramural program of the National Hu-
man Genome Research Institute (to L.G.B.).
Web Resources
Accession numbers and URLs for data presented herein are
as follows:
BLAST, http://www.ncbi.nlm.nih.gov/BLAST/





OMIM, http://www.ncbi.nih.gov/entrez/Omim/ (for BBS)
Sanger Institute, http://www.sanger.ac.uk/ (for L. major)
SGD, http://www.yeastgenome.org/(for S. cerevisiae)
The Institute for Genomic Research, http://www.tigr.org/ (for
T. cruzi)
UniGene, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db
punigene/ (for RefSeq ID numbers NM_014451 and
NM_198428)
References
Adams AE, Rosenblatt M, Suva LJ (1999) Identiﬁcation of a
novel parathyroid hormone-responsive gene in human os-
teoblastic cells. Bone 24:305–313
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990)
Basic local alignment search tool. J Mol Biol 215:403–410
Ansley SJ, Badano JL, Blacque OE, Hill J, Hoskins BE, Leitch
CC, Kim JC, Ross AJ, Eichers ER, Teslovich TM, Mah AK,
Johnsen RC, Cavender JC, Lewis RA, Leroux MR, Beales
PL, Katsanis N (2003) Basal body dysfunction is a likely
cause of pleiotropic Bardet-Biedl syndrome. Nature 425:
628–633
Avidor-Reiss T, Maer AM, Koundakjian E, Polyanovsky A,
Keil T, Subramaniam S, Zuker CS (2004) Decoding cilia
function: deﬁning specialized genes required for compart-
mentalized cilia biogenesis. Cell 117:527–539
Badano JL, Ansley SJ, Leitch CC, Lewis RA, Lupski JR, Kat-
sanis N (2003) Identiﬁcation of a novel Bardet-Biedl syn-
drome protein, BBS7, that shares structural features with
BBS1 and BBS2. Am J Hum Genet 72:650–658
Bardet G (1920) Sur un syndrome d’obesite infantile avec po-
lydactylie et retinite pigmentaire (contribution a l’etude des
formes cliniques de l’obesite hypophysaire). Thesis, Paris
Beales PL, Badano JL, Ross AJ, Ansley SJ, Hoskins BE, Kirsten
B, Mein CA, Froguel P, Scambler PJ, Lewis RA, Lupski JR,
Katsanis N (2003) Genetic interaction of BBS1 mutations
with alleles at other BBS loci can result in non-Mendelian
Bardet-Biedl syndrome. Am J Hum Genet 72:1187–1199
Biedl A (1922) Ein Geschwisterpaar mit adipose-genitaler Dys-
trophie. Dtsch Med Wochenschr 48:1630
Blacque OE, Reardon MJ, Li C, McCarthy J, Mahjoub MR,
Ansley SJ, Badano JL, Mah AK, Beales PL, Davidson WS,
Johnsen RC, Audeh M, Plasterk RH, Baillie DL, Katsanis
N, Quarmby LM, Wicks SR, Leroux MR (2004) Loss of C.
elegans BBS-7 and BBS-8 protein function results in cilia
defects and compromised intraﬂagellar transport. GenesDev
18:1630–1642
Carmi R, Rokhlina T, Kwitek-Black AE, Elbedour K, Nishi-
mura D, Stone EM, Shefﬁeld VC (1995) Use of a DNA
pooling strategy to identify a human obesity syndrome locus
on chromosome 15. Hum Mol Genet 4:9–13
Chiang AP, Nishimura D, Searby C, Elbedour K, Carmi R,
Ferguson AL, Secrist J, Braun T, Casavant T, Stone EM,
Shefﬁeld VC (2004) Comparative genomic analysis identiﬁes
an ADP-ribosylation factor-like gene as the cause of Bardet-
Biedl syndrome (BBS3). Am J Hum Genet 75:475–484
Collins FS, Brooks LD, Chakravarti A (1998) A DNA poly-
morphism discovery resource for research on human genetic
variation. Genome Res 8:1229–1231
Elbedour K, Zucker N, Zalzstein E, Barki Y, Carmi R (1994)
Cardiac abnormalities in the Bardet-Biedl syndrome: echo-
cardiographic studies of 22 patients. Am J Med Genet 52:
164–169
Fan Y, Esmail MA, Ansley SJ, Blacque OE, Boroevich K, Ross
AJ, Moore SJ, Badano JL, May-Simera H, Compton DS,
Green JS, Lewis RA, van Haelst MM, Parfrey PS, Baillie
DL, Beales PL, Katsanis N, Davidson WS, Leroux MR
(2004) Mutations in a member of the Ras superfamily of
Nishimura et al.: Identiﬁcation of BBS9 1033
small GTP-binding proteins causes Bardet-Biedl syndrome.
Nat Genet 36:989–993
Garrod AE (1902) The incidence of alkaptonuria: a study in
chemical individuality. Lancet ii:1616–1620
Green JS, Parfrey PS, Harnett JD, Farid NR, Cramer BC, John-
son G, Heath O, McManamon PJ, O’Leary E, Pryse-Phillips
W (1989) The cardinal manifestations of Bardet-Biedl syn-
drome, a form of Laurence-Moon-Biedl syndrome. N Engl
J Med 321:1002–1009
Harnett JD, Green JS, Cramer BC, Johnson G, Chafe L,
McManamon P, Farid NR, Pryse-Phillips W, Parfrey PS
(1988) The spectrum of renal disease in Laurence-Moon-
Biedl syndrome. N Engl J Med 319:615–618
Hichri H, Stoetzel C, Laurier V, Caron S, Sigaudy S, Sarda P,
Hamel C, Martin-Coignard D, Gilles M, Leheup B, Holder
M, Kaplan J, Bitoun P, Lacombe D, Verloes A, Bonneau D,
Perrin-Schmitt F, Brandt C, Besancon AF, Mandel JL, Cossee
M, Dollfus H (2005) Testing for triallelism: analysis of six
BBS genes in a Bardet-Biedl syndrome family cohort. Eur J
Hum Genet 13:607–616
Katsanis N (2004) The oligogenic properties of Bardet-Biedl
syndrome. Hum Mol Genet 13 Spec No 1:R65–71
Katsanis N, Ansley SJ, Badano JL, Eichers ER, Lewis RA,
Hoskins BE, Scambler PJ, Davidson WS, Beales PL, Lupski
JR (2001) Triallelic inheritance in Bardet-Biedl syndrome, a
Mendelian recessive disorder. Science 293:2256–2259
Katsanis N, Beales PL, Woods MO, Lewis RA, Green JS, Par-
frey PS, Ansley SJ, Davidson WS, Lupski JR (2000) Mu-
tations in MKKS cause obesity, retinal dystrophy and renal
malformations associated with Bardet-Biedl syndrome. Nat
Genet 26:67–70
Kolomietz E, Meyn MS, Pandita A, Squire JA (2002) The role
of Alu repeat clusters as mediators of recurrent chromoso-
mal aberrations in tumors. Genes Chromosomes Cancer 35:
97–112
Kwitek-Black AE, Carmi R, Duyk GM, Buetow KH, Elbedour
K, Parvari R, Yandava CN, Stone EM, Shefﬁeld VC (1993)
Linkage of Bardet-Biedl syndrome to chromosome 16q and
evidence for non-allelic genetic heterogeneity. Nat Genet 5:
392–396
Li JB, Gerdes JM, Haycraft CJ, Fan Y, Teslovich TM, May-
Simera H, Li H, Blacque OE, Li L, Leitch CC, Lewis RA,
Green JS, Parfrey PS, Leroux MR, Davidson WS, Beales PL,
Guay-Woodford LM, Yoder BK, Stormo GD, Katsanis N,
Dutcher SK (2004) Comparative genomics identiﬁes a ﬂa-
gellar and basal body proteome that includes the BBS5 hu-
man disease gene. Cell 117:541–552
Mykytyn K, Braun T, Carmi R, Haider NB, Searby CC, Shastri
M, Beck G, Wright AF, Iannaccone A, Elbedour K, Riise R,
Baldi A, Raas-Rothschild A, Gorman SW, Duhl DM, Ja-
cobson SG, Casavant T, Stone EM, Shefﬁeld VC (2001) Iden-
tiﬁcation of the gene that, when mutated, causes the human
obesity syndrome BBS4. Nat Genet 28:188–191
Mykytyn K, Mullins RF, Andrews M, Chiang AP, Swiderski
RE, Yang B, Braun T, Casavant T, Stone EM, Shefﬁeld VC
(2004) Bardet-Biedl syndrome type 4 (BBS4)-null mice im-
plicate Bbs4 in ﬂagella formation but not global cilia assem-
bly. Proc Natl Acad Sci USA 101:8664–8669
Mykytyn K, Nishimura DY, Searby CC, Shastri M, Yen HJ,
Beck JS, Braun T, Streb LM, Cornier AS, Cox GF, Fulton
AB, Carmi R, Luleci G, Chandrasekharappa SC, Collins FS,
Jacobson SG, Heckenlively JR,Weleber RG, Stone EM, Shef-
ﬁeld VC (2002) Identiﬁcation of the gene (BBS1) most com-
monly involved in Bardet-Biedl syndrome, a complex human
obesity syndrome. Nat Genet 31:435–438
Nishimura DY, Searby CC, Carmi R, Elbedour K, Van Mald-
ergem L, Fulton AB, Lam BL, Powell BR, Swiderski RE,
Bugge KE, Haider NB, Kwitek-Black AE, Ying L, Duhl DM,
Gorman SW, Heon E, Iannaccone A, Bonneau D, Biesecker
LG, Jacobson SG, Stone EM, Shefﬁeld VC (2001) Positional
cloning of a novel gene on chromosome 16q causing Bardet-
Biedl syndrome (BBS2). Hum Mol Genet 10:865–874
Nishimura DY, Swiderski RE, Alward WL, Searby CC, Patil
SR, Bennet SR, Kanis AB, Gastier JM, Stone EM, Shefﬁeld
VC (1998) The forkhead transcription factor gene FKHL7
is responsible for glaucoma phenotypes which map to 6p25.
Nat Genet 19:140–147
Rudiger NS, Gregersen N, Kielland-Brandt MC (1995) One
short well conserved region of Alu-sequences is involved in
human gene rearrangements and has homology with pro-
karyotic chi. Nucl Acids Res 23:256–260
Shefﬁeld VC, Carmi R, Kwitek-Black A, Rokhlina T, Nishi-
mura D, Duyk GM, Elbedour K, Sunden SL, Stone EM
(1994) Identiﬁcation of a Bardet-Biedl syndrome locus on
chromosome 3 and evaluation of an efﬁcient approach to
homozygosity mapping. Hum Mol Genet 3:1331–1335
Slavotinek AM, Stone EM, Mykytyn K, Heckenlively JR,
Green JS, Heon E, Musarella MA, Parfrey PS, Shefﬁeld VC,
Biesecker LG (2000)Mutations inMKKS cause Bardet-Biedl
syndrome. Nat Genet 26:15–16
Swiderski RE, Ying L, Cassell MD, Alward WL, Stone EM,
Shefﬁeld VC (1999) Expression pattern and in situ locali-
zation of the mouse homologue of the human MYOC
(GLC1A) gene in adult brain. Brain Res Mol Brain Res 68:
64–72
Vernon EG, Malik K, Reynolds P, Powlesland R, Dallosso AR,
Jackson S, Henthorn K, Green ED, Brown KW (2003) The
parathyroid hormone-responsive B1 gene is interrupted by
a t(1;7)(q42;p15) breakpoint associated with Wilms’ tum-
our. Oncogene 22:1371–1380
Young TL, Penney L, Woods MO, Parfrey PS, Green JS, Hef-
ferton D, Davidson WS (1999) A ﬁfth locus for Bardet-Biedl
syndrome maps to chromosome 2q31. Am J Hum Genet
64:900–904
